Product Information
BREO ELLIPTA 200-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $5.3573 per EA under NDC 00173088214. Its NADAC has been published 555 times since Dec 23, 2015.
FDA first approved this application on May 10, 2013.
Strength
200; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173088214
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275FDA Approved
5/10/2013
On Market Since
4/30/2015
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 200-25 MCG INHALR has been published 555 times since Dec 23, 2015, and over the history we have for it it has risen 43.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3573 per EA |
|---|---|
| All-time high | $5.3913 (Oct 15, 2025) |
| All-time low | $3.6186 (Apr 20, 2016) |
| 52-week high | $5.3913 |
| 52-week low | $5.3573 |
| Median price | $4.8910 |
| Average price | $4.8206 |
| Largest weekly change | -8.5% (Apr 20, 2016) |
| Weeks tracked | 555 |
| Tracking since | Dec 23, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 200-25 MCG INHALR?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 200-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $5.3573 per EA (NDC 00173088214), effective Aug 19, 2026.
How has the price of BREO ELLIPTA 200-25 MCG INHALR changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has risen 43.6%. It has been tracked across 555 weekly CMS publications since Dec 23, 2015.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 200-25 MCG INHALR?
Since Dec 23, 2015, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has ranged from a low of $3.6186 (Apr 20, 2016) to a high of $5.3913 (Oct 15, 2025), with a median of $4.8910 per EA.
Are there cheaper alternatives to BREO ELLIPTA 200-25 MCG INHALR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BREO ELLIPTA 200-25 MCG INHALR in a comparable dosage form, but none are currently priced below it.
Who manufactures BREO ELLIPTA 200-25 MCG INHALR?
BREO ELLIPTA 200-25 MCG INHALR (NDC 00173088214) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.